Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis

Tetsuji Sawada, Shigeko Inokuma, Takeo Sato, Takeshi Otsuka, Yukihiko Saeki, Tsutomu Takeuchi, Takemasa Matsuda, Tamiko Takemura, Akira Sagawa

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Objective: The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern. The aim of the present study was to elucidate the prevalence and risk factors for newly developed and/or exacerbated ILD, based on post-marketing surveillance data, in which all RA patients receiving LEF were pre-registered and monitored for 24 weeks in Japan. Methods: We analysed data from a cohort of 5054 RA patients who were prescribed LEF since its launch in September 2003 in Japan. Multivariable logistic analysis was performed to identify the risk factors for newly developed and/or exacerbation of ILD. Results: Sixty-one (1.2%) of 5054 RA patients who received LEF were reported to have development and/or exacerbation of ILD as an adverse drug reaction to LEF, judged by the attending physicians. Multivariable logistic regression analysis identified pre-existing ILD [odds ratio (OR) 8.17; 95% CI 4.63, 14.4], cigarette smoking (3.12; 95% CI 1.73, 5.60), a low body weight (<40 kg vs >50 kg) (2.91; 95% CI 1.15, 7.37) and the use of a loading dose (3.97; 95% CI 1.22, 12.9) as independent risk factors for LEF-induced ILD. Conclusions: Pre-existing ILD was the most important risk factor for LEF-induced ILD. We suggest that LEF should not be prescribed for RA patients complicated with ILD.

Original languageEnglish
Pages (from-to)1069-1072
Number of pages4
JournalRheumatology
Volume48
Issue number9
DOIs
Publication statusPublished - 2009 Sep
Externally publishedYes

Fingerprint

leflunomide
Interstitial Lung Diseases
Rheumatoid Arthritis
Japan
Marketing
Drug-Related Side Effects and Adverse Reactions

Keywords

  • Adverse drug reaction
  • Interstitial lung disease
  • Leflunomide
  • Loading dose
  • Rheumatoid arthritis
  • Risk factor
  • Smoking

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Leflunomide-induced interstitial lung disease : Prevalence and risk factors in Japanese patients with rheumatoid arthritis. / Sawada, Tetsuji; Inokuma, Shigeko; Sato, Takeo; Otsuka, Takeshi; Saeki, Yukihiko; Takeuchi, Tsutomu; Matsuda, Takemasa; Takemura, Tamiko; Sagawa, Akira.

In: Rheumatology, Vol. 48, No. 9, 09.2009, p. 1069-1072.

Research output: Contribution to journalArticle

Sawada, T, Inokuma, S, Sato, T, Otsuka, T, Saeki, Y, Takeuchi, T, Matsuda, T, Takemura, T & Sagawa, A 2009, 'Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis', Rheumatology, vol. 48, no. 9, pp. 1069-1072. https://doi.org/10.1093/rheumatology/kep052
Sawada, Tetsuji ; Inokuma, Shigeko ; Sato, Takeo ; Otsuka, Takeshi ; Saeki, Yukihiko ; Takeuchi, Tsutomu ; Matsuda, Takemasa ; Takemura, Tamiko ; Sagawa, Akira. / Leflunomide-induced interstitial lung disease : Prevalence and risk factors in Japanese patients with rheumatoid arthritis. In: Rheumatology. 2009 ; Vol. 48, No. 9. pp. 1069-1072.
@article{07668f6e6467496a8bccdab2894fb1e8,
title = "Leflunomide-induced interstitial lung disease: Prevalence and risk factors in Japanese patients with rheumatoid arthritis",
abstract = "Objective: The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern. The aim of the present study was to elucidate the prevalence and risk factors for newly developed and/or exacerbated ILD, based on post-marketing surveillance data, in which all RA patients receiving LEF were pre-registered and monitored for 24 weeks in Japan. Methods: We analysed data from a cohort of 5054 RA patients who were prescribed LEF since its launch in September 2003 in Japan. Multivariable logistic analysis was performed to identify the risk factors for newly developed and/or exacerbation of ILD. Results: Sixty-one (1.2{\%}) of 5054 RA patients who received LEF were reported to have development and/or exacerbation of ILD as an adverse drug reaction to LEF, judged by the attending physicians. Multivariable logistic regression analysis identified pre-existing ILD [odds ratio (OR) 8.17; 95{\%} CI 4.63, 14.4], cigarette smoking (3.12; 95{\%} CI 1.73, 5.60), a low body weight (<40 kg vs >50 kg) (2.91; 95{\%} CI 1.15, 7.37) and the use of a loading dose (3.97; 95{\%} CI 1.22, 12.9) as independent risk factors for LEF-induced ILD. Conclusions: Pre-existing ILD was the most important risk factor for LEF-induced ILD. We suggest that LEF should not be prescribed for RA patients complicated with ILD.",
keywords = "Adverse drug reaction, Interstitial lung disease, Leflunomide, Loading dose, Rheumatoid arthritis, Risk factor, Smoking",
author = "Tetsuji Sawada and Shigeko Inokuma and Takeo Sato and Takeshi Otsuka and Yukihiko Saeki and Tsutomu Takeuchi and Takemasa Matsuda and Tamiko Takemura and Akira Sagawa",
year = "2009",
month = "9",
doi = "10.1093/rheumatology/kep052",
language = "English",
volume = "48",
pages = "1069--1072",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Leflunomide-induced interstitial lung disease

T2 - Prevalence and risk factors in Japanese patients with rheumatoid arthritis

AU - Sawada, Tetsuji

AU - Inokuma, Shigeko

AU - Sato, Takeo

AU - Otsuka, Takeshi

AU - Saeki, Yukihiko

AU - Takeuchi, Tsutomu

AU - Matsuda, Takemasa

AU - Takemura, Tamiko

AU - Sagawa, Akira

PY - 2009/9

Y1 - 2009/9

N2 - Objective: The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern. The aim of the present study was to elucidate the prevalence and risk factors for newly developed and/or exacerbated ILD, based on post-marketing surveillance data, in which all RA patients receiving LEF were pre-registered and monitored for 24 weeks in Japan. Methods: We analysed data from a cohort of 5054 RA patients who were prescribed LEF since its launch in September 2003 in Japan. Multivariable logistic analysis was performed to identify the risk factors for newly developed and/or exacerbation of ILD. Results: Sixty-one (1.2%) of 5054 RA patients who received LEF were reported to have development and/or exacerbation of ILD as an adverse drug reaction to LEF, judged by the attending physicians. Multivariable logistic regression analysis identified pre-existing ILD [odds ratio (OR) 8.17; 95% CI 4.63, 14.4], cigarette smoking (3.12; 95% CI 1.73, 5.60), a low body weight (<40 kg vs >50 kg) (2.91; 95% CI 1.15, 7.37) and the use of a loading dose (3.97; 95% CI 1.22, 12.9) as independent risk factors for LEF-induced ILD. Conclusions: Pre-existing ILD was the most important risk factor for LEF-induced ILD. We suggest that LEF should not be prescribed for RA patients complicated with ILD.

AB - Objective: The possible link between LEF and interstitial lung disease (ILD) has evoked increasing concern. The aim of the present study was to elucidate the prevalence and risk factors for newly developed and/or exacerbated ILD, based on post-marketing surveillance data, in which all RA patients receiving LEF were pre-registered and monitored for 24 weeks in Japan. Methods: We analysed data from a cohort of 5054 RA patients who were prescribed LEF since its launch in September 2003 in Japan. Multivariable logistic analysis was performed to identify the risk factors for newly developed and/or exacerbation of ILD. Results: Sixty-one (1.2%) of 5054 RA patients who received LEF were reported to have development and/or exacerbation of ILD as an adverse drug reaction to LEF, judged by the attending physicians. Multivariable logistic regression analysis identified pre-existing ILD [odds ratio (OR) 8.17; 95% CI 4.63, 14.4], cigarette smoking (3.12; 95% CI 1.73, 5.60), a low body weight (<40 kg vs >50 kg) (2.91; 95% CI 1.15, 7.37) and the use of a loading dose (3.97; 95% CI 1.22, 12.9) as independent risk factors for LEF-induced ILD. Conclusions: Pre-existing ILD was the most important risk factor for LEF-induced ILD. We suggest that LEF should not be prescribed for RA patients complicated with ILD.

KW - Adverse drug reaction

KW - Interstitial lung disease

KW - Leflunomide

KW - Loading dose

KW - Rheumatoid arthritis

KW - Risk factor

KW - Smoking

UR - http://www.scopus.com/inward/record.url?scp=70349785354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349785354&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kep052

DO - 10.1093/rheumatology/kep052

M3 - Article

C2 - 19321513

AN - SCOPUS:70349785354

VL - 48

SP - 1069

EP - 1072

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 9

ER -